Author: GlobeNewswire

Change in General Management Villepinte France, September 22nd, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions…

Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre-clinical investigational novel compound with…

InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS…

Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with…

Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screeningMENLO PARK, Calif., Sept.…

RESEARCH TRIANGLE PARK, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) — Incyclix Bio, LLC, today announced that Fierce Biotech has named…

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®…

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and…

LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF”…